You searched for venetoclax - Page 4 of 28

ASH 2021: MAJIC – A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

October 12, 2022

In summary, the results of MAJIC will help to inform the selection of time-limited doublet therapy approaches for patients with CLL / SLL and help define the duration of venetoclax in combination with either acalabrutinib or obinutuzumab.

I Was Born for This: My Year on Obinutuzumab and Venetoclax

September 20, 2022

Whenever life throws a challenge my way, I tell myself, “I was born for this.” I reminded myself of this while I went through a year of cancer treatment. It may seem like a strange thing to say to yourself, saying you’re born to face adversity, but that’s the kind of mindset that got me through a challenging time.

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

September 13, 2022

At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jake Soumerai, a clinical investigator at Massachusetts General Hospital and an Assistant Professor at Harvard Medical School. They discussed MRD as a biomarker to direct treatment duration in a phase 2 clinical trial of triple combination venetoclax and obinutuzumab plus zanubrutinib.

ASH 2021: Dr. Talha Munir on Measurable Residual Disease After Fixed-Duration Ibrutinib plus Venetoclax

September 1, 2022

We discuss the latest results from the GLOW study, a phase 3 clinical trial which compared fixed-duration ibrutinib + venetoclax with chemoimmunotherapy (chlorambucil + obinutuzumab) as a first-line treatment.

ASH 2021: Dr. Stephan Stilgenbauer on Venetoclax-Based Time-Limited Combination Treatments for Chronic Lymphocytic Leukemia (CLL)

August 26, 2022

At the annual meeting of the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman, interviewed Dr. Stephan Stilgenbauer, Professor of Medicine at the Comprehensive Cancer Center at Ulm University in Germany. They discussed the latest results from the GAIA (CLL13) trial, which compared rates of measurable residual disease (MRD) with the different treatments.

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

August 25, 2022

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL. This is a powerful combination with impressively durable responses in both TN and R/R patients.

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

August 25, 2022

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, Dr. Bill Wierda of MDACC presented the follow-up three-year data of the fixed duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (treatment) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

ASH 2021: Dr. Nitin Jain on Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Richter’s Transformation

August 17, 2022

We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.

ASH 2021: Dr. Megan Thompson on Outcomes of Subsequent Therapies after Exposure to Bruton’s Tyrosine Kinase Inhibitors and Venetoclax

July 27, 2022

We discuss results from two new studies, which looked at real-world outcomes of subsequent therapies in patients whose disease progressed after either 1) double-exposure to a covalent BTK inhibitor and venetoclax or 2) exposure to a non-covalent BTK inhibitor.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: venetoclax – Page 4

ASH 2021: MAJIC – A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

I Was Born for This: My Year on Obinutuzumab and Venetoclax

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

ASH 2021: Dr. Talha Munir on Measurable Residual Disease After Fixed-Duration Ibrutinib plus Venetoclax

ASH 2021: Dr. Stephan Stilgenbauer on Venetoclax-Based Time-Limited Combination Treatments for Chronic Lymphocytic Leukemia (CLL)

ASCO 2022: Four-year Follow-Up From a Phase 2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASCO 2022: Fixed-duration (FD) Ibrutinib (I) + Venetoclax (V) for First-Line (1L) Treatment (tx) of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Three-Year Follow-Up from the FD Cohort of the Phase 2 CAPTIVATE Study

ASH 2021: Dr. Nitin Jain on Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Richter’s Transformation

ASH 2021: Dr. Megan Thompson on Outcomes of Subsequent Therapies after Exposure to Bruton’s Tyrosine Kinase Inhibitors and Venetoclax

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT